Related Experiment Videos
Therapy for osteoporosis. Miscellaneous and experimental agents
J Y Reginster1, A N Taquet, C Gosset
1Bone and Articular Cartilage Research Unit, University of Liège, Belgium.
Endocrinology and Metabolism Clinics of North America
|July 21, 1998
Summary
Current osteoporosis treatments fail to fully prevent fractures. New therapies like anabolic steroids, growth hormone, and strontium are under investigation to improve osteoporosis management and reduce fracture risk.
Area of Science:
- Bone Metabolism and Therapeutics
- Pharmacology of Osteoporosis
Background:
- Established osteoporosis treatments are insufficient in preventing new vertebral and peripheral fractures.
- There is a critical need for novel therapeutic strategies to optimize the risk/benefit profile in osteoporosis management.
Purpose of the Study:
- To review emerging pharmacologic agents and non-pharmacologic interventions for osteoporosis.
- To discuss the potential of new treatments in preventing osteoporotic fractures.
Main Methods:
- Literature review of current and developing osteoporosis treatments.
- Discussion of anabolic steroids, growth hormone/IGFs, ipriflavone, parathyroid peptides, and strontium.
- Inclusion of hip protectors as a non-pharmacologic approach.
Main Results:
- Several novel compounds are in early stages of development for osteoporosis treatment.
- Anabolic steroids, growth hormone/IGFs, ipriflavone, parathyroid peptides, and strontium are under consideration.
- Hip protectors may offer a reduction in hip fracture incidence.
Conclusions:
- Existing osteoporosis medications do not fully prevent fractures in established disease.
- Investigational therapies show promise for optimizing osteoporosis treatment.
- A combination of pharmacologic and non-pharmacologic approaches may be necessary for comprehensive fracture prevention.